retatrutide phase 2 obesity nejm 2023 jastreboff (Eli Lilly's triple GLP-1/GIP/Glucagon receptor agonist) just delivered the most impressive + osteoarthritis data we've ever seen in the 3 TRIUMPH-4 trial: Precision obesity medicine: A phenotype-guided

Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome

What this means for you You'll need prior authorization, which requires: BMI 30 (or 27 with comorbidities) 6 months documented lifestyle efforts Possible step therapy (trying other medications first) Bottom line: Focus on meeting PA requirements

Frequently Asked Questions No, health insurance is not required to purchase a GLP-1 for hims or Fella Health The amount of weight you can lose depends on your starting point and effort you put in during the treatment

This package ONLY AVAILABLE after initial consultation with Dr

Li Y, Wang S, Li P, Li Y, Liu Y, Fang H, et al

The glucagon receptor component unique to retatrutide increases intestinal motility beyond what GLP-1 alone causes